
GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its Arexvy respiratory syncytial virus (RSV) …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

